Vitamins C and E attenuate plasminogen activator inhibitor-1 (PAI-1) expression in a hypercholesterolemic porcine model of angioplasty

Cardiovascular Research

Volumn 49, Issue 2, 2001, Pages 484-492

  Orbe, Josune ^a   Rodriguez, Jose A ^a   Calvo, Alfonso ^a   Grau, Andres ^a   Belzunce, Maria S ^a   Martinez Caro, Diego ^a   Páramo, Jose A ^a,b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Angioplasty; Atherosclerosis; Cholesterol; Hemostasis; Restenosis

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ANGIOPLASTY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY INJURY; ARTERY INTIMA PROLIFERATION; ARTICLE; CELL MIGRATION; CHOLESTEROL DIET; CONTROLLED STUDY; FIBRINOLYSIS; GENE EXPRESSION; HEMOSTASIS; HYPERCHOLESTEROLEMIA; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MORPHOMETRICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; RESTENOSIS; SWINE;

ANALYSIS OF VARIANCE; ANGIOPLASTY, BALLOON; ANIMALS; ASCORBIC ACID; CHOLESTEROL; DIETARY SUPPLEMENTS; HYPERCHOLESTEROLEMIA; ILIAC ARTERY; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECURRENCE; STATISTICS, NONPARAMETRIC; SWINE, MINIATURE; VITAMIN E;

EID: 0035253801     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(00)00260-1     Document Type: Article

References (48)

1. Restenosis after successful coronary angioplasty: Pathophysiology and prevention
2. Abrupt vessel closure complicating coronary angioplasty: Clinical, angiographic and therapeutic profile
3. Immediate and late outcomes after direct stent implantation without balloon predilation
4. Morphology after transluminal angioplasty in human beings
5. The relative importance of arterial remodeling compared with intimal hyperplasia in lumen renarrowing after balloon angioplasty
6. The implant of atherosclerotic arterial remodeling on percentage of luminal stenosis varies widely within the arterial system
7. Arterial remodeling at the reference site after angioplasty in the atherosclerotic rabbit model
8. Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation
9. Plasminogen activator inhibitor-1-gene-deficient mice, II: Effects on hemostasis, thrombosis and thrombolysis
10. The role of plasminogen activation in smooth muscle cell migration after arterial injury
11. PAI-1 inhibits neointimal formation after arterial injury in mice
12. Role of plasminogen/plasmin system in thrombosis, hemostasis, restenosis and atherosclerosis: Evaluation in transgenic animals
13. Analysis of PAI-1 gene expression in vivo using in situ hybridization
14. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries
15. Plasminogen activator inhibitor in the blood of patients with coronary artery disease
16. ECAT angina pectoris study: Baseline associations of haemostatic factors with extent of coronary arteriosclerosis and other coronary risk factors in 3000 patients with angina pectoris undergoing coronary angiography
17. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris
18. Inhibitors of fibrinolysis are elevated in atherosclerotic plaque
19. Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries
20. Comparative analysis of plasminogen activator inhibitor-1 expression in different types of atherosclerotic lesions in coronary arteries from human heart explants
21. Antioxidants and atherosclerotic heart disease
22. Combination of vitamin C and E alters the response to coronary balloon injury in the pig
23. Antioxidant vitamin-cardiovascular disease hypothesis is still promising, but still unproven: The need for randomized trials
24. Strategies to achieve coronary arterial plaque stabilization
25. Plasma urokinase antigen and plasminogen activator inhibitor-1 antigen levels predict angiographic coronary restenosis
26. Human plasminogen activator inhibitor-1 gene
27. RNA in situ hybridization using digoxigenin-labeled cRNA probes
28. Potentiation by hypercholesterolemia of the induction of aortic intramural synthesis of plasminogen activator inhibitor type 1 by endothelial injury
29. The glucose-oxidase DAB nickel method in peroxidase histochemistry of the nervous system
30. Evidence for a rapid inhibitor to tissue plasminogen activator in plasma
31. Reagent for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency
32. HPLC determination of tocopherol, retinol, dehydroretinol and retinyl palmitate in tissues of lake char (Salvelinus namaycush) exposed to coplanar 3,3′,4,4′,5-pentachlorobiphenyl
33. The atherosclerotic Yucatan animal model to study the arterial response after balloon angioplasty: The natural history of remodeling
34. Regulation of arterial thrombolysis by plasminogen activator-1 in mice
35. Increased intramural expression of plasminogen activator inhibitor type 1 after balloon injury: A potential progenitor of restenosis
36. Changes in arterial expression of fibrinolytic system proteins in atherogenesis
37. Localization of fibrinolytic activators and inhibitors in normal and atherosclerotic vessels
38. Association of fibrinolytic parameters with early atherosclerosis
39. Pravastatin: An antithrombotic effect independent of the cholesterol-lowering effect
40. LDL-hypercholesterolemia is associated with accumulation of oxidized LDL, atherosclerotic plaque growth, and compensatory vessel enlargement in coronary arteries of miniature pigs
41. Vessel size, antioxidants and restenosis
42. Oxidative modification of LDL and atherogenesis
43. 2 production in the pig coronary artery
44. α-Tocopherol inhibits agregation of human platelets by a protein kinase C-dependent mechanism
45. Alpha-tocopherol (vitamin E) regulates vascular smooth muscle cell proliferation and protein kinase C activity
46. Human cardiac microvascular and macrovascular endothelial cells respond differently to oxidatively modified LDL
47. Metabolic abnormalities in renal transplant recipients. Risk factors and predictors of chronic graft dysfunction?
48. Increased plasminogen activator inhibitor-1 and vasculopathy. A reconcilable paradox